MX2022014484A - Lipidos nuevos y composiciones de nanoparticulas de estos. - Google Patents

Lipidos nuevos y composiciones de nanoparticulas de estos.

Info

Publication number
MX2022014484A
MX2022014484A MX2022014484A MX2022014484A MX2022014484A MX 2022014484 A MX2022014484 A MX 2022014484A MX 2022014484 A MX2022014484 A MX 2022014484A MX 2022014484 A MX2022014484 A MX 2022014484A MX 2022014484 A MX2022014484 A MX 2022014484A
Authority
MX
Mexico
Prior art keywords
sup
nanoparticle compositions
novel lipids
lipids
capsid
Prior art date
Application number
MX2022014484A
Other languages
English (en)
Inventor
Birte Nolting
Matthew G Stanton
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MX2022014484A publication Critical patent/MX2022014484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En este documento se proporcionan lípidos que tienen la Fórmula (I): (ver Fórmula) (I); y sales farmacéuticamente aceptables de estos, en donde R1, R1', R2, R2', R3, R3', R4, R4', R5 y R5' son según se define en este documento. También se proporcionan en este documento composiciones de nanopartículas lipídicas (LNP) que comprenden lípidos que tienen la Fórmula (I) y un vector no viral, sin cápside (p. ej., ceADN). En un aspecto, estas LNP pueden utilizarse para administrar un vector de ADN no viral, sin cápside, en un sitio diana de interés (p. ej., célula, tejido, órgano y similares).
MX2022014484A 2020-05-18 2021-05-17 Lipidos nuevos y composiciones de nanoparticulas de estos. MX2022014484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026479P 2020-05-18 2020-05-18
PCT/US2021/032676 WO2021236479A2 (en) 2020-05-18 2021-05-17 Novel lipids and nanoparticle compositions thereof

Publications (1)

Publication Number Publication Date
MX2022014484A true MX2022014484A (es) 2022-12-13

Family

ID=78707483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014484A MX2022014484A (es) 2020-05-18 2021-05-17 Lipidos nuevos y composiciones de nanoparticulas de estos.

Country Status (9)

Country Link
US (1) US20230181764A1 (es)
EP (1) EP4153144A4 (es)
JP (1) JP2023527747A (es)
CN (1) CN115968280A (es)
AU (1) AU2021274481A1 (es)
CA (1) CA3175957A1 (es)
IL (1) IL298241A (es)
MX (1) MX2022014484A (es)
WO (1) WO2021236479A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512578A (ja) 2018-10-09 2022-02-07 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 有機溶媒不含かつ劣化剤不含のトランスフェクション・コンピテント・ベシクルを含む組成物及びシステム並びにそれらに関連する方法
CN114716355B (zh) * 2022-04-02 2023-09-05 华南理工大学 一种脂质化合物、包含其的组合物及应用
CN117925729A (zh) * 2024-01-19 2024-04-26 晟迪生物医药(苏州)有限公司 基于空白脂质纳米颗粒的转染试剂、其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610479D0 (en) * 2006-05-26 2006-07-05 Ge Healthcare Bio Sciences Ab A method for generating metal chelating affinity ligands
JP6093710B2 (ja) * 2011-11-18 2017-03-08 日油株式会社 細胞内動態を改善したカチオン性脂質
EP3252043B1 (en) * 2015-01-30 2020-09-30 NOF Corporation Cationic lipid
CN108348615B (zh) * 2015-10-08 2021-11-12 日油株式会社 O/w型乳液
CN111902397B (zh) * 2018-03-27 2024-04-12 日油株式会社 改进了细胞内动力学的阳离子脂质
CN114929205A (zh) * 2019-09-06 2022-08-19 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
MX2022006033A (es) * 2019-11-22 2022-06-22 Generation Bio Co Lipidos ionizables y composiciones de nanoparticulas de estos.
MX2022007680A (es) * 2019-12-20 2022-09-26 Curevac Ag Nanoparticulas lipidicas para administracion de acidos nucleicos.

Also Published As

Publication number Publication date
US20230181764A1 (en) 2023-06-15
IL298241A (en) 2023-01-01
CA3175957A1 (en) 2021-11-25
WO2021236479A8 (en) 2022-02-24
CN115968280A (zh) 2023-04-14
EP4153144A4 (en) 2024-07-03
WO2021236479A3 (en) 2021-12-23
AU2021274481A1 (en) 2022-11-03
EP4153144A2 (en) 2023-03-29
WO2021236479A2 (en) 2021-11-25
JP2023527747A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
MX2022011988A (es) Nuevos lipidos y composiciones de nanopartículas de estos.
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
MX2022014484A (es) Lipidos nuevos y composiciones de nanoparticulas de estos.
KR102674501B1 (ko) 세포 내 동태를 개선한 신규 양이온성 지질
Mével et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA
WO2022226008A3 (en) Cationic lipids and compositions thereof
JP6640750B2 (ja) カチオン性脂質
Zhi et al. Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery
ES2208763T3 (es) Formulaciones de emulsion para el suministro de acidos nucleicos a las celulas.
ES2432641T3 (es) Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos
SG173183A1 (en) Methods of reducing the proliferation and viability of microbial agents
PT770140E (pt) Composição contendo ácidos nucleicos e polímeros catiónicos, sua preparação e utilização
SG10201407996PA (en) Lipids, lipid compositions, and methods of using them
JP6286646B2 (ja) 新規化合物及びその配合組成物
WO1997030170A1 (de) Zusammensetzung für die transfektion höherer eukaryotischer zellen
WO2019113210A1 (en) Phosphonium-based ionic drug conjugates
CA3189073A1 (en) Lipid conjugates for the delivery of therapeutic agents
WO2001074807A1 (fr) Derives indolylpyrrole et inhibiteurs de mort cellulaire
Zhao et al. Combination of poly (ethylenimine) and chitosan induces high gene transfection efficiency and low cytotoxicity
Fletcher et al. A dialkynoyl analogue of DOPE improves gene transfer of lower-charged, cationic lipoplexes
ES2542864T3 (es) Composición portadora de administración rápida de ácidos nucleicos
EP1152002A4 (en) PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
US20240207187A1 (en) Dendritic architectures as nonviral vectors in gene delivery
WO2021193397A1 (ja) シスチン骨格を有する新規カチオン性脂質
TW201811307A (zh) 2-(2-乙氧基-2-氧代乙基)(甲基)胺基-2-氧代乙基5-(十四烷氧基)呋喃-2-羧酸酯之皮膚調配物